XOLAIR (Genentech, Inc.)
Welcome to the PulseAid listing for the XOLAIR drug offered from Genentech, Inc.. This Anti-IgE [EPC],Decreased IgE Activity [PE],IgE-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Genentech, Inc. |
NON-PROPRIETARY NAME: | omalizumab |
SUBSTANCE NAME: | OMALIZUMAB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Anti-IgE [EPC],Decreased IgE Activity [PE],IgE-directed Antibody Interactions [MoA] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2003-06-20 |
END MARKETING DATE: | 0000-00-00 |
XOLAIR HUMAN PRESCRIPTION DRUG Details:
Item Description | XOLAIR from Genentech, Inc. |
LABELER NAME: | Genentech, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 202.5(mg/1.4mL) |
START MARKETING DATE: | 2003-06-20 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 50242-040_7eafb2a9-969a-41c2-b0f5-113765912803 |
PRODUCT NDC: | 50242-040 |
APPLICATION NUMBER: | BLA103976 |
Other OMALIZUMAB Pharmaceutical Manufacturers / Labelers: